Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Novo Nordisk A/S (NYSE:NVO) is ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Hims & Hers (HIMS) stock plummeted nearly 35% Monday after Novo Nordisk (NVO) announced it was ending a collaboration to make its blockbuster weight-loss drug, Wegovy, available on Hims' telehealth ...

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...